290 related articles for article (PubMed ID: 11196162)
1. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
5. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.
Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M
Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329
[TBL] [Abstract][Full Text] [Related]
6. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.
Gozzini A; Rovida E; Dello Sbarba P; Galimberti S; Santini V
Cancer Res; 2003 Dec; 63(24):8955-61. PubMed ID: 14695213
[TBL] [Abstract][Full Text] [Related]
7. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
9. Targeting aberrant transcriptional repression in acute myeloid leukemia.
Moe-Behrens GH; Pandolfi PP
Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
[TBL] [Abstract][Full Text] [Related]
10. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
11. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
12. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
13. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
14. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells.
Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V
Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169
[TBL] [Abstract][Full Text] [Related]
15. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G
Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells.
Cras A; Darsin-Bettinger D; Balitrand N; Cassinat B; Soulié A; Toubert ME; Delva L; Chomienne C
Oncogene; 2007 Jun; 26(27):4018-24. PubMed ID: 17213810
[TBL] [Abstract][Full Text] [Related]
17. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
18. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Fazi F; Travaglini L; Carotti D; Palitti F; Diverio D; Alcalay M; McNamara S; Miller WH; Lo Coco F; Pelicci PG; Nervi C
Oncogene; 2005 Mar; 24(11):1820-30. PubMed ID: 15688037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]